Liminatus Pharma announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance

Liminatus Pharma, Inc.

Board approved 1-for-50 reverse stock split; effective at close of trading Aug 20, 2026; split-adjusted trading on Nasdaq Capital Market Aug 21, 2026 under LIMN.
Outstanding shares would drop from 67,160,362 to ~1,343,208 (as of July 2, 2026); fractional shares rounded up; CUSIP changes to 53271X 207.
Nasdaq Panel granted transfer to Capital Market effective Aug 4, 2026; must show $1.00 closing bid for 10 consecutive days by Sept 3, 2026 to regain compliance.
Company had been non-compliant with MVLS, MVPHS, and bid price rules; regained compliance with stockholders' equity and MVPHS requirements.

item 3.01 item 3.03 item 5.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.